The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On October 13, 2022, the Shenzhen Stock Exchange disclosed that the 73rd Review Meeting of the GEM Listing Committee in 2022 was held and approved Jiaxing Quaero Life Science Co., Ltd. to be listed on the Sci-Tech Innovation Board.

Standard BioTools — formerly Fluidigm — said on Thursday that its Biomark and Juno molecular diagnostic systems have received approval from China's National Medical Products Administration.

GE published a regulatory filing about the spinoff of its healthcare unit, which it expects to complete in the first week of 2023, if the transaction is approved by its board of directors. GE HealthCare will be listed on the Nasdaq under the ticker “GEHC.”

QuidelOrtho on Wednesday reported preliminary third quarter revenues of between $782 million and $785 million.

Illumina said on Tuesday that it has entered into a strategic research collaboration with AstraZeneca on drug target discovery.

Amoy (300685.SZ) and Beigene (NASDAQ: BGNE, HKEX: 06160, SSE: 688235) have recently entered into a strategic collaboration on companion diagnostics.

Beckman Coulter Diagnostics said Tuesday that it has acquired StoCastic, a startup informatics company that develops artificial intelligence-based clinical decision support for hospital emergency departments. Financial terms were not disclosed.

Wall Street had a mixed reaction to a report that Bio-Rad Laboratories and Qiagen are in talks about a possible merger.

September 21, Merck, a leading global technology company, announced the opening of the first phase of its EUR 29 million biosafety testing laboratory in China, a virus clearance validation laboratory. The 5,000 square meter center is Merck's first laboratory of its kind in China.

Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals.